局所ドラッグデリバリー市場は、2025年の2,684億米ドルから2030年には4,090億米ドルに達し、予測期間中のCAGRは8.8%になると予測されています。外用ドラッグデリバリー市場における著名なプレーヤーは、Johnson & Johnson Services, Inc.(米国)、Galderma(スイス)、Bayer AG(ドイツ)、Novartis AG(スイス)、AbbVie Inc.(米国)、GSK Plc.(英国)、Bausch Health Companies Inc.(カナダ)、Glenmark Pharmaceuticals Limited(インド)、久光製薬株式会社 (日本)、Cipla(インド)、Boehringer Ingelheim International GmbH(ドイツ)、Pfizer Inc.(米国)、Teva Pharmaceuticals Industries Ltd.(イスラエル)、 Viatris Inc.(米国)、Organonグループ企業(米国)、Solventum(米国)、Crescita Therpeautics Inc.(カナダ)、Luye Pharma Group(中国)、リードケミカル株式会社 (日本)、Purdue Pharma L.P.(米国)、Lavipharm(ギリシャ)、CMP Pharma, Inc.(ドイツ)、Encore Dermatology, Inc.(米国)、Rusan Pharma Ltd.(インド)、AdhexPharma(フランス)。
目次
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.2.2 MARKETS & REGIONS COVERED
1.2.3 YEARS CONSIDERED
1.2.4 CURRENCY CONSIDERED
1.3 MARKET STAKEHOLDERS
1.4 LIMITATIONS
1.5 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH METHODOLOGY DESIGN
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Key data from primary sources
2.2.2.2 Key industry insights
2.3 MARKET SIZE ESTIMATION
2.3.1 APPROACH 1: REVENUE SHARE ANALYSIS
2.3.2 APPROACH 2: PHARMACEUTICAL SALES ANALYSIS
2.3.3 APPROACH 3: TOP-DOWN APPROACH
2.3.4 APPROACH 4: BOTTOM-UP APPROACH
2.3.5 APPROACH 4: PRIMARY INTERVIEWS
2.3.6 APPROACH 5: DEMAND-SIDE APPROACH
2.3.7 APPROACH 6: VOLUME DATA ANALYSIS
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
2.5 MARKET SHARE ANALYSIS
2.6 STUDY ASSUMPTIONS
2.6.1 GROWTH RATE ASSUMPTIONS
2.7 RISK ASSESSMENT
2.8 LIMITATIONS
2.8.1 METHODOLOGY-RELATED LIMITATIONS
2.8.2 SCOPE-RELATED LIMITATIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 TOPICAL DRUG DELIVERY MARKET OVERVIEW
4.2 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT & COUNTRY (2024)
4.3 TOPICAL DRUG DELIVERY MARKET: REGIONAL MIX
4.4 TOPICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.5 TOPICAL DRUG DELIVERY MARKET: DEVELOPED MARKETS VS. EMERGING ECONOMIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing prevalence of skin disorders
5.2.1.2 High incidence of burn injuries
5.2.1.3 Growing emphasis on patient convenience
5.2.1.4 Increasing investments in pharmaceutical R&D
5.2.1.5 Rising incidence of chronic diseases
5.2.2 RESTRAINTS
5.2.2.1 Adverse skin reactions & allergies
5.2.2.2 Drug failure & recalls of TDD systems
5.2.2.3 High development costs of topical drug delivery products
5.2.3 OPPORTUNITIES
5.2.3.1 Growing preference for self-administration and home care
5.2.3.2 High growth potential of emerging economies
5.2.4 CHALLENGES
5.2.4.1 Technical barriers related to skin irritation & permeability
5.3 INDUSTRY TRENDS
5.3.1 ADVANCES IN TRANSDERMAL DRUG DELIVERY SYSTEMS
5.3.2 EMERGENCE OF MICRONEEDLE PATCH TECHNOLOGIES
5.4 TECHNOLOGY ANALYSIS
5.4.1 KEY TECHNOLOGIES
5.4.1.1 Nanocarrier-based delivery systems
5.4.1.2 Microemulsions & nanoemulsion
5.4.1.3 Thermosensitive & pH-sensitive hydrogels & hydrocolloids
5.4.2 COMPLEMENTARY TECHNOLOGIES
5.4.2.1 Microneedle-enhanced delivery
5.4.2.2 AI-assisted formulations & prediction models
5.4.3 ADJACENT TECHNOLOGIES
5.4.3.1 Wearable sensor-integrated topical patches
5.4.3.2 3D testing skin models
5.5 PORTER'S FIVE FORCES ANALYSIS
5.5.1 THREAT OF NEW ENTRANTS
5.5.2 THREAT OF SUBSTITUTES
5.5.3 BARGAINING POWER OF SUPPLIERS
5.5.4 BARGAINING POWER OF BUYERS
5.5.5 INTENSITY OF COMPETITIVE RIVALRY
5.6 REGULATORY LANDSCAPE
5.6.1 REGULATORY ANALYSIS
5.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.7 PATENT ANALYSIS
5.7.1 PATENT PUBLICATION TRENDS FOR TOPICAL DRUG DELIVERY
5.7.2 INSIGHTS: JURISDICTION & TOP APPLICANT ANALYSIS
5.8 TRADE ANALYSIS
5.8.1 TRADE DATA FOR HS CODE 300490
5.8.1.1 Import data for HS Code 300490
5.8.1.2 Export data for HS Code 300490
5.9 PRICING ANALYSIS
5.9.1 AVERAGE SELLING PRICE TREND, BY PRODUCT, 2022-2024
5.9.2 AVERAGE SELLING PRICE OF OINTMENTS, BY KEY PLAYER, 2024
5.9.3 AVERAGE SELLING PRICE OF GELS, BY KEY PLAYER, 2024
5.9.4 AVERAGE SELLING PRICE, BY REGION
5.9.5 AVERAGE SELLING PRICE OF SEMI-SOLID FORMULATIONS, BY REGION, 2024
5.9.5.1 Average selling price trend of ointments, by region, 2022-2024
5.9.5.2 Average selling price trend of creams, by region, 2022-2024
5.9.5.3 Average selling price trend of gels, by region, 2022-2024
5.10 REIMBURSEMENT ANALYSIS
5.11 KEY CONFERENCES & EVENTS, 2025-2026
5.12 KEY STAKEHOLDERS & BUYING CRITERIA
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.12.2 BUYING CRITERIA
5.13 UNMET NEEDS/END-USER EXPECTATIONS
5.14 IMPACT OF AI ON TOPICAL DRUG DELIVERY MARKET
5.14.1 AI-USE CASES
5.15 PIPELINE ANALYSIS
5.16 ECOSYSTEM MARKET MAP
5.17 VALUE CHAIN ANALYSIS
5.18 INVESTMENT & FUNDING SCENARIO
5.19 TRUMP TARIFF IMPACT ON TOPICAL DRUG DELIVERY MARKET
5.19.1 INTRODUCTION
5.19.2 KEY TARIFF RATES
5.19.3 PRICE IMPACT ANALYSIS
5.19.4 KEY IMPACT ON VARIOUS REGIONS
5.19.5 END-USE INDUSTRY IMPACT
6 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 SEMI-SOLID FORMULATIONS
6.2.1 OINTMENTS
6.2.1.1 Wide applications in analgesic indications to drive market
6.2.2 CREAMS
6.2.2.1 High absorption capabilities to boost demand
6.2.3 LOTIONS
6.2.3.1 Convenient application to fuel uptake
6.2.4 GELS
6.2.4.1 Enhanced patient compliance and aesthetic appeal to drive market
6.2.5 PASTES
6.2.5.1 Prevention of skin irritation to fuel uptake
6.3 LIQUID FORMULATIONS
6.3.1 SUSPENSIONS
6.3.1.1 Higher rate of bioavailability and controlled onset of action to drive market
6.3.2 EMULSIONS
6.3.2.1 Versatile carriers for enhanced drug delivery to fuel uptake
6.3.3 SOLUTIONS
6.3.3.1 Uniform & rapid drug delivery to boost demand
6.4 SOLID FORMULATIONS
6.4.1 POWDERS
6.4.1.1 Inexpensive manufacturing and effectiveness against antifungal infections to propel market
6.4.2 SUPPOSITORIES
6.4.2.1 Ability to ensure drug compatibility to fuel market
6.4.3 FILM
6.4.3.1 Next-generation advancements to boost demand
6.5 TRANSDERMAL PRODUCTS
6.5.1 TRANSDERMAL PATCHES
6.5.1.1 Drug-in-adhesive patches
6.5.1.1.1 Enhanced drug release to fuel uptake
6.5.1.2 Matrix patches
6.5.1.2.1 Rising technological advancements to boost demand
6.5.1.3 Reservoir membrane patches
6.5.1.3.1 Prolonged drug delivery to fuel market
6.5.1.4 Microneedle patches
6.5.1.4.1 Ability to deliver APIs to support market growth
6.5.1.5 Iontophoresis patches
6.5.1.5.1 Low molecular weight patches to support market growth
6.5.1.6 Vapor patches
6.5.1.6.1 Ability to release essential oils to support market growth
6.5.2 TRANSDERMAL GELS
6.5.2.1 Rapid release of drugs to fuel uptake
6.5.3 TRANSDERMAL SPRAYS
6.5.3.1 Targeted approach to boost demand
6.6 OTHER PRODUCTS
7 TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION
7.1 INTRODUCTION
7.2 DERMAL DRUG DELIVERY
7.2.1 STANDARD MEDIUM WITH HIGH DRUG ABSORPTION TO PROPEL MARKET
7.3 OPHTHALMIC DRUG DELIVERY
7.3.1 FOCUS ON MICROEMULSION-BASED FORMULATIONS TO BOOST DEMAND
7.4 VAGINAL DRUG DELIVERY
7.4.1 LIMITED INTERVENTION BY MEDICAL PERSONNEL TO DRIVE MARKET
7.5 RECTAL DRUG DELIVERY
7.5.1 COMBINATION OF LOCAL & SYSTEMIC THERAPY OF DRUGS TO FUEL UPTAKE
7.6 NASAL DRUG DELIVERY
7.6.1 QUICK ONSET OF DRUG ACTION & CONVENIENCE TO SUPPORT MARKET UPTAKE
8 TOPICAL DRUG DELIVERY MARKET, BY END USER
8.1 INTRODUCTION
8.2 HOME CARE SETTINGS
8.2.1 HIGH PREFERENCE, AFFORDABILITY, AND CONVENIENCE TO PROPEL MARKET
8.3 HOSPITALS & CLINICS
8.3.1 ADOPTION OF TOPICAL ANAESTHETICS FOR MEDICAL & SURGICAL SUB-SPECIALTIES TO DRIVE MARKET
8.4 AMBULATORY SURGERY CENTERS
8.4.1 UTILIZATION OF ANTIMICROBIAL TOPICAL DRUGS FOR TRAUMA CASES TO BOOST DEMAND
8.5 BURN CARE CENTERS
8.5.1 HIGH INCIDENCE OF BURN INJURIES AND UPTAKE OF OINTMENTS TO SUPPORT MARKET GROWTH
8.6 OTHER END USERS
9 TOPICAL DRUG DELIVERY MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
9.2.2 US
9.2.2.1 Rising prevalence of skin diseases to drive market
9.2.3 CANADA
9.2.3.1 Rising prevalence of hypertension and funding for topical drugs research to drive market growth
9.3 EUROPE
9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
9.3.2 GERMANY
9.3.2.1 Growing focus of R&D for pharmaceutical API development to boost demand
9.3.3 UK
9.3.3.1 Rising demand for painless treatment alternatives to fuel market
9.3.4 FRANCE
9.3.4.1 Rising incidence of diabetes and subsequent increase in skin lesions to drive market
9.3.5 ITALY
9.3.5.1 Rising demand for transdermal patches to propel market
9.3.6 SPAIN
9.3.6.1 Expanding research hub to fuel market
9.3.7 NETHERLANDS
9.3.7.1 Public awareness initiatives for preventive care to fuel uptake
9.3.8 REST OF EUROPE
9.4 ASIA PACIFIC
9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
9.4.2 CHINA
9.4.2.1 Rising cases of communicable diseases to drive market
9.4.3 JAPAN
9.4.3.1 Increasing number of product approvals to drive market
9.4.4 INDIA
9.4.4.1 Growing focus on adoption of non-invasive drug delivery methods to drive market
9.4.5 AUSTRALIA
9.4.5.1 Increasing number of smokers to fuel uptake
9.4.6 SOUTH KOREA
9.4.6.1 Favorable government focus on expanding clinical trials to boost demand
9.4.7 THAILAND
9.4.7.1 Regulatory reforms and supportive healthcare initiatives to support market growth
9.4.8 VIETNAM
9.4.8.1 Increasing investments and regulatory reforms to fuel uptake
9.4.9 REST OF ASIA PACIFIC
9.5 LATIN AMERICA
9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
9.5.2 BRAZIL
9.5.2.1 High prevalence of diabetes to propel market growth
9.5.3 MEXICO
9.5.3.1 Increasing prevalence of glaucoma to drive market
9.5.4 REST OF LATIN AMERICA
9.6 MIDDLE EAST & AFRICA
9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
9.6.2 GCC COUNTRIES
9.6.2.1 Kingdom of Saudi Arabia (KSA)
9.6.2.1.1 Expanding healthcare infrastructure to boost demand
9.6.2.2 United Arab Emirates (UAE)
9.6.2.2.1 Increasing prevalence of diabetes to fuel uptake
9.6.2.3 Other GCC Countries
9.6.3 REST OF MIDDLE EAST & AFRICA
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN TOPICAL DRUG DELIVERY MARKET
10.3 REVENUE ANALYSIS, 2020-2024
10.4 MARKET SHARE ANALYSIS
10.4.1 RANKING OF KEY MARKET PLAYERS
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
10.5.5.1 Company footprint
10.5.5.2 Region footprint
10.5.5.3 Product footprint
10.5.5.4 Site of application footprint
10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
10.6.1 PROGRESSIVE COMPANIES
10.6.2 RESPONSIVE COMPANIES
10.6.3 DYNAMIC COMPANIES
10.6.4 STARTING BLOCKS
10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
10.6.5.1 Detailed list of key startups/SME players
10.6.5.2 Competitive benchmarking of key emerging players/startups
10.7 BRAND/PRODUCT COMPARISON
10.7.1 TOPICAL DRUG DELIVERY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
10.8 R&D EXPENDITURE OF KEY PLAYERS
10.8.1 R&D EXPENDITURE OF KEY PLAYERS IN TOPICAL DRUG DELIVERY MARKET
10.9 COMPANY VALUATION & FINANCIAL METRICS
10.9.1 FINANCIAL METRICS
10.9.2 COMPANY VALUATION
10.10 COMPETITIVE SCENARIO
10.10.1 PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS
10.10.2 DEALS
10.10.3 EXPANSIONS
10.10.4 OTHER DEVELOPMENTS
11 COMPANY PROFILES
11.1 KEY PLAYERS
11.1.1 JOHNSON & JOHNSON SERVICES, INC.
11.1.1.1 Business overview
11.1.1.2 Products offered
11.1.1.3 Recent developments
11.1.1.3.1 Product approvals
11.1.1.3.2 Deals
11.1.1.4 MnM view
11.1.1.4.1 Key strengths
11.1.1.4.2 Strategic choices
11.1.1.4.3 Weaknesses & competitive threats
11.1.2 GALDERMA
11.1.2.1 Business overview
11.1.2.2 Products offered
11.1.2.3 Recent developments
11.1.2.3.1 Product launches & approvals
11.1.2.3.2 Deals
11.1.2.3.3 Expansions
11.1.2.4 MnM view
11.1.2.4.1 Key strengths
11.1.2.4.2 Strategic choices
11.1.2.4.3 Weaknesses & competitive threats
11.1.3 BAYER AG
11.1.3.1 Business overview
11.1.3.2 Products offered
11.1.3.3 Recent developments
11.1.3.3.1 Product launches & approvals
11.1.3.3.2 Deals
11.1.3.4 MnM view
11.1.3.4.1 Key strengths
11.1.3.4.2 Strategic choices
11.1.3.4.3 Weaknesses & competitive threats
11.1.4 NOVARTIS AG
11.1.4.1 Business overview
11.1.4.2 Products offered
11.1.4.3 Recent developments
11.1.4.3.1 Deals
11.1.4.3.2 Other developments
11.1.4.4 MnM view
11.1.4.4.1 Key strengths
11.1.4.4.2 Strategic choices
11.1.4.4.3 Weaknesses & competitive threats
11.1.5 ABBVIE INC.
11.1.5.1 Business overview
11.1.5.2 Products offered
11.1.5.3 Recent developments
11.1.5.3.1 Product launches
11.1.5.3.2 Expansions
11.1.5.3.3 Other developments
11.1.5.4 MnM view
11.1.5.4.1 Key strengths
11.1.5.4.2 Strategic choices
11.1.5.4.3 Weaknesses & competitive threats
11.1.6 GLENMARK PHARMACEUTICALS LIMITED
11.1.6.1 Business overview
11.1.6.2 Products offered
11.1.6.3 Recent developments
11.1.6.3.1 Product approvals
11.1.6.3.2 Deals
11.1.7 GSK PLC.
11.1.7.1 Business overview
11.1.7.2 Products offered
11.1.7.3 Recent developments
11.1.7.3.1 Deals
11.1.7.3.2 Other developments
11.1.8 BAUSCH HEALTH COMPANIES INC.
11.1.8.1 Business overview
11.1.8.2 Products offered
11.1.8.3 Recent developments
11.1.8.3.1 Product launches & approvals
11.1.8.3.2 Deals
11.1.9 HISAMITSU PHARMACEUTICAL CO., INC.
11.1.9.1 Business overview
11.1.9.2 Products offered
11.1.9.3 Recent developments
11.1.9.3.1 Product launches, enhancements, and approvals
11.1.9.3.2 Deals
11.1.9.3.3 Expansions
11.1.10 CIPLA
11.1.10.1 Business overview
11.1.10.2 Products offered
11.1.10.3 Recent developments
11.1.10.3.1 Deals
11.1.11 VIATRIS INC.
11.1.11.1 Business overview
11.1.11.2 Products offered
11.1.11.3 Recent developments
11.1.11.3.1 Product launches & approvals
11.1.11.3.2 Deals
11.1.11.3.3 Other developments
11.1.12 ORGANON GROUP OF COMPANIES
11.1.12.1 Business overview
11.1.12.2 Products offered
11.1.12.3 Recent developments
11.1.12.3.1 Product approvals
11.1.12.3.2 Deals
11.1.13 PFIZER, INC.
11.1.13.1 Business overview
11.1.13.2 Products offered
11.1.13.3 Recent developments
11.1.13.3.1 Product approvals
11.1.13.3.2 Deals
11.1.14 CRESCITA THERAPEUTICS INC.
11.1.14.1 Business overview
11.1.14.2 Products offered
11.1.14.3 Recent developments
11.1.14.3.1 Deals
11.1.14.3.2 Other developments
11.1.15 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
11.1.15.1 Business overview
11.1.15.2 Products offered
11.1.15.3 Recent developments
11.1.15.3.1 Deals
11.1.15.3.2 Expansions
11.1.16 TEVA PHARMACEUTICAL INDUSTRIES LTD.
11.1.16.1 Business overview
11.1.16.2 Products offered
11.1.16.3 Recent developments
11.1.16.3.1 Deals
11.1.17 SOLVENTUM
11.1.17.1 Business overview
11.1.17.2 Products offered
11.1.17.3 Recent developments
11.1.17.3.1 Deals
11.1.18 LUYE PHARMA GROUP
11.1.18.1 Business overview
11.1.18.2 Products offered
11.1.18.3 Recent developments
11.1.18.3.1 Product approvals
11.1.18.3.2 Deals
11.1.19 LEAD CHEMICAL CO., LTD.
11.1.19.1 Business overview
11.1.19.2 Products offered
11.1.20 PURDUE PHARMA L.P.
11.1.20.1 Business overview
11.1.20.2 Products offered
11.1.21 LAVIPHARM
11.1.21.1 Business overview
11.1.21.2 Products offered
11.2 OTHER PLAYERS
11.2.1 CMP PHARMA, INC.
11.2.2 ENCORE DERMATOLOGY, INC.
11.2.3 RUSAN PHARMA LTD.
11.2.4 ADHEXPHARMA
12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
12.3 RELATED REPORTS
12.4 AUTHOR DETAILS
